Picture Kentro Design Corporate and Web Design Berlin 650x65px
Document › Details

Randox Laboratories Ltd.. (11/23/15). "Press Release: Randox Laboratories and Biosytems International Announce Completion of Clinical Trial and Licencing for QuantiPlasma Antibodies for Early Lung Cancer Diagnostics".

Region Region ALL
Organisations Organisation Randox Laboratories Ltd.
  Group Randox (Group)
  Organisation 2 BioSystems International Kft.
  Group BioSystems International (Group)
Products Product cancer test, early detection
  Product 2 QuantiPlasma™ antibodies
Index term Index term Randox–Biosystems International: lung cancer test, 201511– license ww for blood-based mAB lung cancer test for early detection
Persons Person Takacs, Laszlo (BioSystems International 200512 CEO)
  Person 2 Lamont, John (Randox 201511 Chief Scientist)

Randox Laboratories and Biosystems International today announced the beginning of clinical validation of a lung cancer early detection test.

A recent clinical trial involving over 1100 samples has been carried out in partnership with BioDiagnostica Kft across four leading lung cancer treatment centers in Hungary, and the promising results have resulted in advancing the test for further clinical validation.

Lung cancer is the most common cancer worldwide, with over 1.8 million new cases diagnosed in 2012 (13% of total cancer diagnosis)1. As most lung cancer cases are diagnosed at a late stage this test provides an opportunity for earlier diagnosis across the world.

Randox Chief Scientist, John Lamont, comments: “This large study has produced some exciting results and we are looking towards validating the test to bring it to a wider market. This blood test can play a significant part in the early detection of lung cancer and distributing it to a global market will support easier and early diagnosis of this disease.”

Laszlo Takacs, CEO and CTO of Biosystems International adds: “Our mAb libraries proved to be valuable for detecting both qualitative and quantitative variability of the proteome in cancer. With Randox we are looking forward to continuing towards market introduction of the early detection test for lung cancer”.

Biosystems International Kft, BioDiagnostica Kft and Randox have signed a licencing agreement which enables Randox to distribute the test globally.

Record changed: 2019-04-26


Picture [LSUS] – The Business Web Portal 650x65px

More documents for Randox (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Kentro Design Corporate and Web Design Berlin 650x65px

» top